MarketWatchCenter·
The FDA declined to approve one of biotech’s most closely watched cancer drugs
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Read at MarketWatch →
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
<iframe src="https://statesidedaily.com/embed/cluster/c089c89e6e44963e8776d25c12c9b7ee854e4d7a" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="The FDA declined to approve one of biotech’s most closely watched cancer drugs"></iframe>